<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81971">
  <stage>Registered</stage>
  <submitdate>4/05/2007</submitdate>
  <approvaldate>8/05/2007</approvaldate>
  <actrnumber>ACTRN12607000246482</actrnumber>
  <trial_identification>
    <studytitle>Radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast.</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 07.01 - A randomised phase III study of radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast to improve time to recurrence</scientifictitle>
    <utrn />
    <trialacronym>DCIS</trialacronym>
    <secondaryid>Breast International Group (BIG) 3-07</secondaryid>
    <secondaryid>ClinicalTrials.gov ID NCT00470236</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Completely excised non-low risk DCIS</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Women will be randomised to receive one of the following four treatments: 
- Whole breast RT alone using standard fractionation schedule 50 Gy / 25 fractions over 35 days
- Whole breast RT alone using shorter fractionation schedule 42.5 Gy / 16 fractions over 22 days
- Whole breast RT plus tumour bed boost using standard fractionation schedule - 50 Gy / 25 fractions over 35 days plus 10 Gy / 5 fractions over 5 days
- Whole breast RT plus tumour bed boost using shorter fractionation schedule - 42.5 Gy / 16 fractions over 22 days plus 10 Gy / 4 fractions over 4 days</interventions>
    <comparator>Whole breast RT alone using standard fractionation schedule 50 Gy / 25 fractions over 35 days</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to local recurrence - The time from randomisation to the time of recurrent invasive or intraductal disease in any soft tissue of the ipsilateral breast. </outcome>
      <timepoint>Main analysis after all patients have completed 5 years of follow-up. Updated analysis after 10 years of follow-up.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival </outcome>
      <timepoint>The time from randomisation to the time of death from any cause. Main analysis after all patients have completed 5 years of follow-up. Updated analysis after 10 years of follow-up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to disease recurrence </outcome>
      <timepoint>The time from randomisation to the time of any recurrence. Main analysis after all patients have completed 5 years of follow-up. Updated analysis after 10 years of follow-up. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cosmetic outcome  </outcome>
      <timepoint>Cosmetic outcome will be assessed using the following instruments: EORTC Cosmetic Rating System and Quantitative assessment of breast cosmesis. Assessed at baseline, 12, 36 and 60 months post Radiotherapy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Radiation toxicity - The NCI</outcome>
      <timepoint>Assessed at baseline, last week of RT, 3, 6, and 12 months post RT and then yearly until year 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Common Terminology Criteria version 3.0 will be used for serious adverse event and toxicity reporting. </outcome>
      <timepoint>Assessed at baseline, last week of RT, 3, 6, and 12 months post RT and then yearly until year 10.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life  </outcome>
      <timepoint>Assessed at baseline, last week of RT, 3, 6, and 12 months post RT and then yearly until year 10.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Women aged &gt;18years.
2. Histologically proven DCIS of the breast without an invasive component.
3. Bilateral mammograms performed within 6 months prior to randomisation.
3. Clinically node-negative.
4. Treated by breast conserving surgery (primary excision or re-excision) with complete microscopic excision and clear radial margins of greater than or equal to 1mm (Patients with superficial or deep resection margin of &lt;1 mm are eligible if surgery has removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia)
5. Women who are at high risk of local recurrence due to: Age &lt; 50 years; OR Age = 50 years plus at least one of the following: a) Symptomatic presentation
b) Palpable tumour c) Multifocal disease
d) Microscopic tumour size = 1.5 cm in maximum dimension e) Intermediate or high nuclear grade f) Central necrosis
g) Comedo histology h) Radial* surgical resection margin &lt; 10 mm*Patients with superficial or deep resection margin of &lt; 10 mm are eligible if surgery has not removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia.
6. Assessed by surgeon and radiation oncologist to be suitable for breast conserving therapy including whole breast RT.
7. Ability to tolerate protocol treatment.
8. Protocol RT should preferably commence within 8 weeks but must commence no later than 12 weeks from the last surgical procedure
9. ECOG performance status 0, 1 or 2.
10. Patients life expectancy &gt; 5 years
11. Availability for long-term follow-up.
12. Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who fulfil any of the following criteria are not eligible for admission to study:- 
1. Multicentric disease or extensive microcalcifications that could not be completely excised by breast conserving surgery with radial margins of greater than or equal to 1mm (Patients with superficial and/or deep margin of &lt; 1mm are eligible if surgery has removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia)
2. Presence of tumour cells in lymph nodes detected using H&amp;E or immunohistochemical examination (if lymph node biopsy or dissection has been performed).
3. Locally recurrent breast cancer.
4. Previous DCIS or invasive cancer of the contralateral breast.
5. Other concurrent or previous malignancies except: a) Non-melanomatous skin cancer; b) Carcinoma in situ of the cervix or endometrium; and
c) Invasive carcinoma of the cervix, endometrium, colon, thyroid and melanoma treated at least five years prior to study admission without disease recurrence.
6. Serious non-malignant disease that precludes definitive surgical or radiation treatment (e.g. scleroderma, systemic lupus erythematosus, cardiovascular/pulmonary/renal disease).- 7. ECOG performance status = 3.
8. Women who are pregnant or lactating.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone /computer</concealment>
    <sequence>Stratified allocation. Factors: Age (&lt; 50, = 50), Surgical margin (&lt; 1 mm, = 1 mm), Endocrine therapy (yes, no), centre</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2007</anticipatedstartdate>
    <actualstartdate>25/06/2007</actualstartdate>
    <anticipatedenddate>1/10/2014</anticipatedenddate>
    <actualenddate>25/06/2014</actualenddate>
    <samplesize>1600</samplesize>
    <actualsamplesize>1607</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Trans Tasman Radiation Oncology Group Ltd</primarysponsorname>
    <primarysponsoraddress>Department of Radiation Oncology
Calvary Mater Newcastle
Locked Bag 7 Hunter Region Mail Centre
NSW 2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council Project Grant</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Please delete</sponsorname>
      <sponsoraddress>Please delete</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Breast International Group (BIG)</othercollaboratorname>
      <othercollaboratoraddress>Institut Jules Bordet
Blvd de Waterloo 121, 7th fl
B-1000 Brussels</othercollaboratoraddress>
      <othercollaboratorcountry>Belgium</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname />
      <othercollaboratoraddress>Department of Surgical Oncology
Calvary Mater Newcastle
Locked Bag 7 Hunter Region Mail Centre
NSW 2310</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>European Organisation for Research and Treatment of Cancer</othercollaboratorname>
      <othercollaboratoraddress>EORTC AISBL / IVZW
Avenue Mounieriaan, 83/11
Brussel 1200 Bruxelles</othercollaboratoraddress>
      <othercollaboratorcountry>Belgium</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Canadian Cancer Trials Group</othercollaboratorname>
      <othercollaboratoraddress>New other collaborator address. Please modify.</othercollaboratoraddress>
      <othercollaboratorcountry>Canada</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>International Breast Cancer Study Group</othercollaboratorname>
      <othercollaboratoraddress>Effingerstrasse 40
3008 Bern
Switzerland</othercollaboratoraddress>
      <othercollaboratorcountry>Switzerland</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>All Ireland Cooperative Oncology Research Group</othercollaboratorname>
      <othercollaboratoraddress>60 Fitzwilliam Square, Dublin 2, Ireland</othercollaboratoraddress>
      <othercollaboratorcountry>Ireland</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Scottish Cancer Trials Breast Group</othercollaboratorname>
      <othercollaboratoraddress>1 South Gyle Crescent,
Edinburgh EH12 9EB,</othercollaboratoraddress>
      <othercollaboratorcountry>United Kingdom</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aims
- To refine treatment selection for women with non-low risk DCIS to optimise disease control &amp; minimise toxicity 
- Clinical: To evaluate outcomes after breast conserving surgery by investigating two factors
- Addition of tumour bed boost to whole breast RT
- Dose fractionation
- QoL  To compare QoL, psychological distress, perceived risk of invasive disease &amp; perceived cosmetic outcomes amongst treatment arms
- Biological: To identify biomarkers/molecular signatures of DCIS predictive of invasive recurrence for therapy individualisation</summary>
    <trialwebsite />
    <publication>07.01 (DCIS): A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast

Presented by Boon Chua at the Breast International Group Specific Meeting, Vienna, Austria March 2017</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>4/05/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Boon Chua</name>
      <address>Medical Professorial Unit
Level 1, South Wing, Edmund Blackett Building
Prince of Wales Hospital, High Street, Randwick, NSW 2031</address>
      <phone>+61 (0) 2 9382 8873 </phone>
      <fax />
      <email>Boon.Chua@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Rachel Galettis</name>
      <address>TROG Cancer Research
PO Box 88
Waratah, NSW 2298</address>
      <phone>+61 2 401 43921</phone>
      <fax>+61 2 401 43902</fax>
      <email>rachel.galettis@trog.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>TROG Cancer Research
Central Operations Office
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3910  </phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Boon Chua</name>
      <address>Medical Professorial Unit
Level 1, South Wing, Edmund Blackett Building
Prince of Wales Hospital, High Street, Randwick, NSW 2031
</address>
      <phone>+61 (0) 2 9382 8873 </phone>
      <fax />
      <email>Boon.Chua@health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>